Search
Menu
Home
Sources
About
Contacts
Opiranserin
Opiranserin
is a
selective
and
combined
glycine
GlyT2
transporter blocker
,
purine
P2X
3
receptor antagonist
, and
serotonin
5-HT
2A
receptor
antagonist
which is
under development
by Vivozon for the
intravenous
treatment
of
postoperative pain
. As of
April 2017
, it is
in phase
II
clinical trials
for this
indication
. The of the
drug
was issued in
2017
.